Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CADL

Candel Therapeutics Inc

Dec 13 • 04:00PM ET

6.75

Dollar change -3.05
Percentage change -31.12	%

Healthcare • Biotechnology • USA • NASD

Peers: ADAP IMTX XBIT ZNTL ATHA MRNS PPBT BLRX LPTX ADIL

| Held by: IWM VTI IWO VXF VFMO VTWO IWC VTWG RSSL UWM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.74	Insider Own	37.53%	Shs Outstand	32.13M	Perf Week	31.32%
Market Cap	150.99M	Forward P/E	45.00	EPS next Y	0.15	Insider Trans	-3.58%	Shs Float	20.29M	Perf Month	57.34%
Income	-52.20M	PEG	-	EPS next Q	-0.30	Inst Own	14.78%	Short Float	10.74%	Perf Quarter	-7.28%
Sales	0.00M	P/S	-	EPS this Y	-25.95%	Inst Trans	15.02%	Short Ratio	0.90	Perf Half Y	-7.41%
Book/sh	-0.47	P/B	-	EPS next Y	109.09%	ROA	-145.85%	Short Interest	2.18M	Perf Year	467.23%
Cash/sh	0.74	P/C	9.12	EPS next 5Y	-	ROE	-1344.47%	52W Range	1.02 - 14.60	Perf YTD	359.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.75%	ROI	-	52W High	-53.77%	Beta	-1.00
Dividend TTM	-	Quick Ratio	1.18	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	561.76%	ATR (14)	1.47
Dividend Ex-Date	-	Current Ratio	1.18	EPS Y/Y TTM	-57.70%	Oper. Margin	-	RSI (14)	56.74	Volatility	42.85% 19.32%
Employees	42	Debt/Eq	-	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	11.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-14.02%	Payout	-	Rel Volume	7.68	Prev Close	9.80
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Nov 14 BMO	Avg Volume	2.42M	Price	6.75
SMA20	32.97%	SMA50	26.17%	SMA200	13.50%	Trades		Volume	18,606,225	Change	-31.12%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-22	Initiated	H.C. Wainwright	Buy	$11
Nov-19-21	Initiated	BMO Capital Markets	Outperform	$18
Aug-23-21	Initiated	UBS	Buy	$9
Aug-23-21	Initiated	Jefferies	Buy	$22
Aug-23-21	Initiated	Credit Suisse	Outperform	$15

Dec-12-24 11:00PM	Candel Therapeutics Announces Pricing of Public Offering (GlobeNewswire) +26.45% -31.12%
04:51PM	Candel Therapeutics Announces $80 Million Proposed Public Offering (GlobeNewswire)
Dec-11-24 04:09PM	Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug (Investor's Business Daily) +68.11%
01:07PM	Candel Therapeutics Prostate Cancer Therapy Shows Promise (Exec Edge)
11:54AM	Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug (Investor's Business Daily)
10:32AM	Loading…
10:32AM	Candel Therapeutics stock up 172% after Phase III prostate cancer success (Clinical Trials Arena)
09:19AM	Candel Therapeutics Stock Surges Over 100% - Here's Why (Benzinga)
07:00AM	Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival (GlobeNewswire)
Nov-14-24 08:00AM	Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-07-24 08:00AM	Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024 (GlobeNewswire)
Nov-05-24 09:00AM	Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma (GlobeNewswire)
Oct-29-24 08:59AM	Candel Therapeutics Advances in Cancer Treatment Trials (TipRanks)
Oct-28-24 08:00AM	Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC) (GlobeNewswire)
Oct-04-24 09:00AM	Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting (GlobeNewswire)
Sep-04-24 08:00AM	Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors (GlobeNewswire)
08:00AM	Loading…
Sep-03-24 08:00AM	Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.52%
Aug-13-24 08:00AM	Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Jun-18-24 08:00AM	Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire) -6.93%
Jun-14-24 08:30AM	Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments (News Direct)
07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-11-24 08:00AM	Candel Therapeutics to Join Russell 3000 Index (GlobeNewswire) +7.40%
Jun-07-24 08:30AM	Candel Therapeutics' (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers (News Direct)
Jun-03-24 08:30AM	Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer (News Direct) -5.96%
May-30-24 08:00AM	FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma (GlobeNewswire)
May-28-24 11:07AM	Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why (Zacks) +9.62%
May-24-24 11:42AM	Candel (CADL) Reports Upbeat Data From Lung Cancer Study (Zacks) -27.03%
May-23-24 05:00PM	Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting (GlobeNewswire)
11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
08:00AM	Loading…
May-22-24 08:00AM	Candel Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -13.77%
May-20-24 08:00AM	Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting (GlobeNewswire)
May-15-24 11:14AM	Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection (PR Newswire) +30.84%
May-14-24 01:53PM	CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024 (InvestorPlace)
08:00AM	Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire) -7.94%
Apr-25-24 08:00AM	Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting (GlobeNewswire) +6.28%
Apr-12-24 10:00AM	Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag (Zacks) -8.52%
Apr-11-24 09:00AM	Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer (GlobeNewswire) +42.75%
Apr-09-24 08:00AM	Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors (GlobeNewswire) -20.84%
Apr-05-24 12:10PM	Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study (Zacks)
Apr-04-24 12:24PM	After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study (Benzinga) +280.95%
08:00AM	Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire)
Mar-28-24 04:05PM	Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma (GlobeNewswire) +10.76%
01:53PM	CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
08:05AM	Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-15-24 08:15AM	Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors (News Direct)
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 04:30PM	Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate (GlobeNewswire)
Feb-13-24 07:30AM	CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma (GlobeNewswire) +29.50%
Feb-05-24 08:00AM	Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts (GlobeNewswire)
Dec-13-23 12:21PM	Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409 (Zacks) +17.82%
Dec-12-23 08:00AM	Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer (GlobeNewswire) +16.29%
Nov-28-23 09:00AM	Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN Discovery Platform, and Key Clinical Readouts for CAN-2409 (GlobeNewswire) -8.16%
Nov-09-23 09:43AM	Candel Therapeutics Inc (CADL) Reports Q3 2023 Financial Results and Clinical Progress (GuruFocus.com) -13.00%
08:00AM	Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-04-23 08:00AM	Candel Therapeutics Presents Preclinical Data from its enLIGHTEN Discovery Platform at SITC (GlobeNewswire)
Nov-03-23 12:00PM	Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire) -21.50%
Oct-18-23 11:00AM	Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110 (GlobeNewswire)
Sep-27-23 09:40AM	Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting (GlobeNewswire) -9.00%
Sep-26-23 08:00AM	Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer (GlobeNewswire) -10.71%
Sep-06-23 08:00AM	Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 08:00AM	Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-02-23 08:00AM	Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jun-13-23 08:00AM	Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024 (GlobeNewswire)
Jun-08-23 08:00AM	Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors (GlobeNewswire) +5.30%
Jun-05-23 08:00AM	Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (GlobeNewswire) +9.80%
May-22-23 08:26AM	Favourable Signals For Candel Therapeutics: Numerous Insiders Acquired Stock \ (Simply Wall St.) +7.64%
May-19-23 01:51PM	Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer (Benzinga) -8.15%
09:00AM	Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire)
May-11-23 08:00AM	Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-02-23 08:00AM	Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO (GlobeNewswire) +15.44%
Apr-17-23 08:00AM	Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer (GlobeNewswire) +19.01%
Mar-30-23 08:00AM	Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research) +5.54%
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research) +6.46%
Mar-06-23 07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research)
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research)
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
Feb-28-23 06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research) -9.01%
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-24-23 07:17AM	Daily Vickers Top Insider Picks for 02/24/2023 (Argus Research)
Feb-23-23 07:21AM	Daily Vickers Top Insider Picks for 02/23/2023 (Argus Research)
Feb-22-23 06:56AM	Daily Vickers Top Insider Picks for 02/22/2023 (Argus Research) -5.28%
Feb-21-23 07:35AM	Daily Vickers Top Insider Picks for 02/21/2023 (Argus Research)
Feb-17-23 06:27AM	Daily Vickers Top Insider Picks for 02/17/2023 (Argus Research)
Feb-16-23 07:28AM	Daily Vickers Top Insider Picks for 02/16/2023 (Argus Research)
Feb-15-23 07:01AM	Daily Vickers Top Insider Picks for 02/15/2023 (Argus Research)
Feb-14-23 06:23AM	Daily Vickers Top Insider Picks for 02/14/2023 (Argus Research)
Feb-13-23 07:30AM	Daily Vickers Top Insider Picks for 02/13/2023 (Argus Research)
Feb-10-23 06:42AM	Daily Vickers Top Insider Picks for 02/10/2023 (Argus Research) -8.86%
Feb-09-23 06:51AM	Daily Vickers Top Insider Picks for 02/09/2023 (Argus Research)
Feb-08-23 06:45AM	Daily Vickers Top Insider Picks for 02/08/2023 (Argus Research)
Feb-07-23 06:46AM	Daily Vickers Top Insider Picks for 02/07/2023 (Argus Research)
Feb-06-23 06:56AM	Daily Vickers Top Insider Picks for 02/06/2023 (Argus Research) -6.20%
Feb-03-23 06:32AM	Daily Vickers Top Insider Picks for 02/03/2023 (Argus Research)
Feb-02-23 06:43AM	Daily Vickers Top Insider Picks for 02/02/2023 (Argus Research)
Feb-01-23 08:00AM	Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day (GlobeNewswire) -6.21%
06:14AM	Daily Vickers Top Insider Picks for 02/01/2023 (Argus Research)

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tyagarajan Seshu	Chief Technology Officer	Nov 29 '24	Sale	4.56	20,392	92,898	125,657	Dec 03 05:48 PM
Tak Paul Peter	Chief Executive Officer	Nov 29 '24	Sale	4.56	48,847	222,527	294,788	Dec 03 05:48 PM
Nichols William Garrett	Chief Medical Officer	Nov 29 '24	Sale	4.56	13,935	63,482	100,547	Dec 03 05:47 PM
Barone Francesca	Chief Scientific Officer	Nov 29 '24	Sale	4.56	22,081	100,592	137,880	Dec 03 05:46 PM
Tyagarajan Seshu	Officer	Nov 29 '24	Proposed Sale	4.95	18,548	91,813		Nov 29 09:17 AM
Tak Paul Peter	Officer	Nov 29 '24	Proposed Sale	4.95	44,433	219,943		Nov 29 09:15 AM
Nichols William Garrett	Officer	Nov 29 '24	Proposed Sale	4.95	12,675	62,741		Nov 29 09:13 AM
Barone Francesca	Officer	Nov 29 '24	Proposed Sale	4.95	20,085	99,421		Nov 29 09:12 AM
Tak Paul Peter	Chief Executive Officer	Nov 21 '24	Option Exercise	1.55	12,900	19,995	343,635	Nov 21 03:07 PM
Aguilar-Cordova Estuardo	10% Owner	Oct 11 '24	Sale	6.05	15,000	90,750	944,873	Oct 15 05:59 PM
Aguilar-Cordova Estuardo	10% Owner	Oct 14 '24	Sale	6.02	15,000	90,300	929,873	Oct 15 05:59 PM
Aguilar-Cordova Estuardo	10% Owner	Oct 15 '24	Sale	6.03	10,412	62,784	919,461	Oct 15 05:59 PM
Aguilar-Cordova Estuardo	10% Owner	Oct 02 '24	Sale	6.92	26,988	186,757	961,673	Oct 03 06:19 PM
Aguilar-Cordova Estuardo	10% Owner	Oct 03 '24	Sale	6.85	1,800	12,330	959,873	Oct 03 06:19 PM
Aguilar-Cordova Estuardo	Director	Sep 23 '24	Proposed Sale	7.00	28,480	199,360		Sep 23 05:16 PM
Aguilar-Cordova Estuardo	Director	Sep 13 '24	Proposed Sale	6.50	28,840	187,460		Sep 13 05:53 PM
Tyagarajan Seshu	Chief Technology Officer	Jul 17 '24	Sale	6.47	14,851	96,125	146,049	Jul 19 08:31 AM
Tak Paul Peter	Chief Executive Officer	Jul 17 '24	Sale	6.47	22,528	145,815	330,735	Jul 19 08:29 AM
Schoch Charles	See Remarks	Jul 17 '24	Sale	6.47	9,884	63,975	62,520	Jul 19 08:28 AM
Nichols William Garrett	Chief Medical Officer	Jul 17 '24	Sale	6.47	10,875	70,390	114,482	Jul 19 08:26 AM
Barone Francesca	Chief Scientific Officer	Jul 17 '24	Sale	6.47	14,051	90,947	159,961	Jul 19 08:24 AM
Tyagarajan Seshu	Chief Technology Officer	Jul 11 '24	Sale	5.97	13,330	79,625	160,900	Jul 15 08:36 AM
Tak Paul Peter	Chief Executive Officer	Jul 11 '24	Sale	5.97	20,293	121,218	353,263	Jul 15 08:35 AM
Schoch Charles	See Remarks	Jul 11 '24	Sale	5.97	8,897	53,145	72,404	Jul 15 08:34 AM
Nichols William Garrett	Chief Medical Officer	Jul 11 '24	Sale	5.97	9,769	58,354	125,357	Jul 15 08:32 AM
Barone Francesca	Chief Scientific Officer	Jul 11 '24	Sale	5.97	12,645	75,534	174,012	Jul 15 08:30 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CADL

Candel Therapeutics Inc

Upgrade your FINVIZ experience